The Alliance for Regenerative Medicine Announces 2019 Cell & Gene Meeting on the Mediterranean

WASHINGTON, D.C. – July 13, 2018

The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector, announced it will hold its first annual Cell & Gene Meeting on the Mediterranean on April 23-24, 2019 in Barcelona, Spain.

The event, modeled after the organization’s highly successful Cell & Gene Meeting on the Mesa held annually in La Jolla, California, is expected to attract more than 250 attendees, including senior executives from leading cell therapy, gene therapy, and tissue engineering companies worldwide, large pharma and biotech representatives, institutional investors, academic research institutions, patient foundations, disease philanthropies, and members of the life science media community.

“The aim of this meeting is to highlight and further accelerate the growth of the regenerative medicine field in Europe and globally,” said Janet Lambert, CEO of ARM. “This ‘Meeting on the Med’ will be a valuable resource to sector stakeholders who are tracking and shaping the rapid advancement of advanced therapies in Europe and worldwide.

This program will feature expert-led panels, fireside chats, extensive one-on-one partnering capabilities, exclusive networking opportunities, and dedicated presentations by the leading publicly-traded and privately-held companies in the space. The meeting will cover a wide range of commercialization topics from reimbursement and regulatory issues to manufacturing and financing, with 50+ speakers and panelists and addressing critical commercial, scientific, and regulatory issues. More than 40 prominent publicly traded and emerging private companies will highlight their clinical and commercial progress to interested partners and investors.

Additional event details will be updated regularly on the event website –
Registration will open in early September with discounted early-bird rates available through January 15, 2019. Registration is complimentary for investors and credentialed members of the media. To learn more and to register, please visit For members of the media interested in attending, please contact Lyndsey Scull at

For interested organizations looking to increase exposure to this field’s top decision-makers via sponsorship, please contact Laura Parsons at for additional information.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 290 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit

# # #